Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetuximab/fluorouracil/folinic acid/irinotecan - OxSonics Therapeutics

Next Previous
X
Search
Drug Profile

Cetuximab/fluorouracil/folinic acid/irinotecan - OxSonics Therapeutics

Alternative Names: Cetuximab/FOLFIRI - OxSonics Therapeutics; Fluorouracil/folinic acid/irinotecan/Cetuximab - OxSonics Therapeutics; FOLFIRI/Cetuximab - OxSonics Therapeutics

Latest Information Update: 25 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OxSonics Therapeutics
  • Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Formyltetrahydrofolates; Immunotherapies; Indolizines; Monoclonal antibodies; Piperidines; Pyrans; Pyrimidinones; Quinolines; Quinolones; Vitamins
  • Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; DNA synthesis inhibitors; DNA topoisomerase I inhibitors; Epidermal growth factor receptor antagonists; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Colorectal cancer

Highest Development Phases

  • Phase I/II Colorectal cancer

Most Recent Events

  • 23 Jan 2023 Adverse events data from a phase I/II trial in Colorectal cancer (Metastatic disease) released by OxSonics Therapeutics
  • 07 Oct 2022 Cetuximab/fluorouracil/folinic acid/irinotecan is available for licensing as of 07 Oct 2022. https://oxsonics.com/partnering-programme/ (OxSonics Therapeutics pipeline, October 2022)
  • 07 Oct 2022 Preclinical pharmacodynamics data from in Colorectal cancer and Lung cancer released by OxSonics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top